The aim of the proposed research is to assess the neuronal mechanisms underlying certain behavioral effects of indole- and phenylalkylamine hallucinogens (e.g., LSD [d-lysergic acid diethylamide] and mescaline [3,4,5-trimethoxyphenylthylamine]), central nervous system (CNS) stimulants (e.g., d-amphetamine and cocaine) and the so-called """"""""designer"""""""" drugs, MDA (3,4-methylenedioxyamphetamine) and MDMA (3,4- methylenedioxymethamphetamine), which appear to have both hallucinogenic and stimulant properties. Our principle behavioral procedure will continue to be drug discrimination which has been of considerable value in advancing our understanding of drug actions and has served as an excellent, if not unique animal model of the subjective effects of hallucinogenic and related substances in humans. The reasons we continue to use this admittedly difficult and time-consuming assay include the fact that it is pharmacologically specific in that substitution of a novel compound for a training drug (generalization of a drug """"""""cue"""""""") usually reflects common mechanisms of action rather than simply psychoactive effects and blockade of the stimulus properties of a training or test drug (during a combination test) normally requires that the """"""""agonist"""""""" and """"""""antagonist"""""""" compounds have similar receptor actions. In addition, drug discrimination is sensitive in that it is able to reliably assess the behavioral effects of very small doses of drugs such as LSD and lisuride and reliable, possibly because it uses response choice rather than rate as its primary dependent variable and thereby avoids confounds caused by unconditioned effects of test or training drugs on motor behavior. Finally, drug discrimination results correlate highly with neurochemical (e.g., receptor binding) results; thus, this procedure has acquired respectability as a pharmacological assay by confirming behavioral (in vivo) relevance to in vitro or ex vivo findings.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37DA002543-21
Application #
2116603
Study Section
Special Emphasis Panel (NSS)
Project Start
1980-04-01
Project End
1999-03-31
Budget Start
1994-04-15
Budget End
1995-03-31
Support Year
21
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of South Carolina at Columbia
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
111310249
City
Columbia
State
SC
Country
United States
Zip Code
29208
Alici, Tevfik; Appel, James B (2004) Increasing the selectivity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol: complete substitution with methanandamide. Pharmacol Biochem Behav 79:431-7
Appel, James B; West, William B; Buggy, James (2004) LSD, 5-HT (serotonin), and the evolution of a behavioral assay. Neurosci Biobehav Rev 27:693-701
West, W B; Lou, A; Pechersky, K et al. (2000) Antagonism of a PCP drug discrimination by hallucinogens and related drugs. Neuropsychopharmacology 22:618-25
Appel, J B; West, W B; Rolandi, W G et al. (1999) Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 64:353-8
Simon, B; Appel, J B (1997) Dopaminergic and serotonergic properties of fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry 21:169-81
West, W B; Van Groll, B J; Appel, J B (1995) Stimulus effects of d-amphetamine II: DA, NE, and 5-HT mechanisms. Pharmacol Biochem Behav 51:69-76
Callahan, P M; Appel, J B; Cunningham, K A (1991) Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology (Berl) 103:50-5
Cunningham, K A; Callahan, P M; Appel, J B (1987) Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics. Eur J Pharmacol 138:29-36